Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms-Reference-Cited by-同舟云学术

Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms

Published:2023-08-20 Issue:24 Volume:41 Page:3984-3987
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Cliff Edward R. Scheffer¹²^ORCID,Kesselheim Aaron S.¹²^ORCID,Feldman William B.¹²^ORCID

Affiliation:

1. Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA

2. Harvard Medical School, Boston, MA

Abstract

@Eddie_Cliff et al explore the scientific & ethical reasons why patients randomized to the control arm of trials should 'crossover' to receive the investigational therapy if their disease progresses

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02675

Reference36 articles.

1. Equipoise and the Ethics of Clinical Research

2. Equipoise and the Dilemma of Randomized Clinical Trials

3. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

4. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

5. Treatment of Mantle-Cell Lymphoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma;Journal of Clinical Oncology;2024-07-25

2. Improving Collection and Analysis of Overall Survival Data;Clinical Cancer Research;2024-07-17

3. A novel framework to assess haematology and oncology registration trials: The THEOREMM project;European Journal of Clinical Investigation;2024-06-27

4. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis;The Lancet Oncology;2024-06

5. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review;Cancer Treatment Reviews;2024-01